Kepivance Европейски съюз - български - EMA (European Medicines Agency)

kepivance

swedish orphan biovitrum ab (publ) - палиферминът - мукозит - Всички други терапевтични продукти - kepivance е показан за намаляване на честотата, продължителността и тежестта на гъбични заболявания при възрастни пациенти с хематологични неоплазии, получаващи myeloablative radiochemotherapy, свързани с висока честота на сериозни заболявания и изискващи поддръжка на автологични хемопоетична стволови клетки.

Jardiance Европейски съюз - български - EMA (European Medicines Agency)

jardiance

boehringer ingelheim international gmbh - empagliflozin - diabetes mellitus, type 2; heart failure; renal insufficiency, chronic - Лекарства, използвани при диабет - type 2 diabetes mellitusjardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesfor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 и 5. of the annex. heart failurejardiance is indicated in adults for the treatment of symptomatic chronic heart failure.  chronic kidney diseasejardiance is indicated in adults for the treatment of chronic kidney disease.

Lipertance  10 mg/5 mg/5 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lipertance  10 mg/5 mg/5 mg film - coated tablets

les laboratoires servier - Аторвастатин, периндоприл и амлодипин - 10 mg/5 mg/5 mg film - coated tablets

Lipertance  20 mg/5 mg/5 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lipertance  20 mg/5 mg/5 mg film - coated tablets

les laboratoires servier - Периндоприл, аторвастатин и амлодипин - 20 mg/5 mg/5 mg film - coated tablets

Lipertance  20 mg/10 mg/5 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lipertance  20 mg/10 mg/5 mg film - coated tablets

les laboratoires servier - Аторвастатин, периндоприл и амлодипин - 20 mg/10 mg/5 mg film - coated tablets

Lipertance  20 mg/10 mg/10 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lipertance  20 mg/10 mg/10 mg film - coated tablets

les laboratoires servier - Периндоприл, аторвастатин и амлодипин - 20 mg/10 mg/10 mg film - coated tablets

Lipertance  40 mg/10 mg10 mg film - coated tablets България - български - Изпълнителна агенция по лекарствата

lipertance  40 mg/10 mg10 mg film - coated tablets

les laboratoires servier - Периндоприл, аторвастатин и амлодипин - 40 mg/10 mg10 mg film - coated tablets

Rozlytrek Европейски съюз - български - EMA (European Medicines Agency)

rozlytrek

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - Антинеопластични средства - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

Tavneos Европейски съюз - български - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - Имуносупресори - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).